Synthetic Carbohydrate-based Glycomedicine Development

While many currently used glycomedicines are composed of naturally derived glycans, important advances in carbohydrate chemistry have enabled the development of chemically defined conjugated constructs against a number of pathogens and infectious diseases. CD BioGlyco provides customized services for synthetic carbohydrate-based glycomedicine development.

The Necessity for Synthetic Techniques

A major obstacle in glycobiology and glycomedicine is the lack of pure and structurally well-defined carbohydrates and glycoconjugates. These compounds are often found in low concentrations and in microheterogeneous forms, greatly complicating their isolation and characterization. In many cases, well-defined carbohydrates can only be obtained by chemical- or enzymatic synthesis and such compounds are increasingly used to address important problems in glycobiology research and for vaccine and drug discovery.

Since chemical or enzymatic synthesis is a powerful method not only for the construction of natural polysaccharides, but also for the design of non-natural polysaccharide analogues having tailored biological functions. It is a promising strategy for creating bioactive polysaccharides and their analogues by utilizing polysaccharides found in nature.

Structures of the Brucella O-antigen and their synthetic oligosaccharides and glycoconjugates.Fig.1 Structures of the Brucella O-antigen and their synthetic oligosaccharides and glycoconjugates (Mettu, et al., 2020)

Synthetic Carbohydrate-based Glycomedicine Development Services

Enzymatic and chemical modifications are commonly used in the development of synthetic carbohydrate-based glycomedicines. CD BioGlyco has established an advanced carbohydrate-based glycomedicine development platform and a variety of methods to meet the special needs of customers. Our methods include but are not limited to:

  • Enzymatic tailoring to remodel the glycans after expression.
  • Chemically defined synthetic methodologies to create glycosidic linkages in a selective and site-specific fashion.
  • Rational design of potent inhibitors for several lectin targets involved in disease states, including selectins, adhesins, and galectins. 
  • Development of multivalent glycan structures, including glycodendrimers, glyconanoparticles, and glycoclusters, to improve affinity to proteins by mimicking the multivalent nature of interactions between lectins and their natural carbohydrate ligands.

Advantages of Us

  • Increased in vivo stability and improved bioactivity.
  • Various modifications can be customized according to each special need.
  • Advanced technology platforms and professional research teams.

CD BioGlyco offers advanced customization services for the development of synthetic carbohydrate-based glycomedicines such as anti-inflammatory drugs. If you are interested in our services, please contact us for further consultation.

Reference:

  1. Mettu, R.; et al. Synthetic carbohydrate-based vaccines: challenges and opportunities. Journal of Biomedical Science. 2020, 27(1): 9.
This service is for Research Use Only, not intended for any clinical use.

Christmas

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.